UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~June 123, 2014

BIOJECT MEDICAL TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-15360

Oregon		93-1099680
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
7180 SW Sandburg St., Ste. 100 Tigard, Oregon		97223
(Address of principal executive offices)		(Zip Code)

7180 SW Sandburg Street, Suite 100 Tigard, Oregon		97223
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (503) 692-8001

Former name or former address if changed since last report:

No Change

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 52.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition

On ~~July~~August 115, 2014, Bioject Medical Technologies Inc. (~~the~~ “~~Company~~Bioject”) ~~announced~~ issued a press release announcing its unaudited financial results for the second ~~departure~~quarter ofended ~~Christine~~June 30, M2014. ~~Farrell,~~The ~~Vice~~press ~~President~~release ofincludes ~~Finance~~cautionary ~~and~~statements ~~the~~identifying ~~appointment~~important offactors ~~Tony~~that Kcould cause actual results to differ materially from those anticipated. ~~Chow,~~The ~~age~~press 65release issued August 15, 2014, is furnished herewith as ~~the~~Exhibit ~~Company’s~~No. 99.1 ~~Chief~~to ~~Financial~~this ~~Officer~~Report, and ~~Corporate~~shall ~~Secretary~~not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

~~From~~Item ~~1999 to 2013 prior to joining the Company, Mr~~8. ~~Chow~~01 ~~was~~Other a consultant in financial and operational management roles for domestic and international companies. Mr. Chow consulted in the areas of SEC reporting, financial/IT/J-SOX compliance reporting, and internal/external audits on a project or interim basis. Most recently, Mr. Chow was the Chief Financial Officer at American Laser Healthcare Corporation, a development stage medical device company with SEC reporting. Mr. Chow brings professional services experience with over 30 years in financial management consulting, financial operations including SEC reporting, financial/IT/J SOX compliance, business development, client relationship management, and software product development/implementations. From 1997 to 1999, Mr. Chow was the Director of Asia Sales and Marketing at Digital Video Systems, Inc. From 1994 to 1997, Mr. Chow was the Chief Financial Officer and Corporate Controller at Craig Consumer Electronics, Inc. From 1989 to 1993, Mr. Chow was the Controller of InterTherapy, Inc., a start-up company in the manufacturing and marketing on intravasculathreer ultrasound imaging system and catheter. Mr. Chow holds an MBA degree in Finance, Accounting and Operations Research from the University of California at Riverside. He also earned a BA degree in Economics from the University of the Pacific at Stockton, and a BA degree in Physiology from the University of California at Berkeley. Events

~~Pursuant~~On toAugust 11, 2014, the ~~Agreement~~Board of Directors of Bioject Medical Technologies, Mr Inc. ~~Chow~~ ~~will~~approved ~~formally~~two ~~serve~~secured asnotes ~~the~~for ~~Company’s~~advances ~~Chief~~of ~~Financial~~capital ~~Officer~~made ofto ~~the~~Bioject, ~~Company~~due ~~effective~~to ~~July~~a cash flow shortfall in June 2014. The Mark A. Logomasini 1& Associates, ~~2014~~Inc. ~~and~~SEP heFund (“SEP”) ~~will~~and ~~receive~~Amir anNess ~~annual~~advanced ~~salary~~Bioject of$100,000 and $9050,000, ~~subject~~respectively, toon ~~review~~June 23, atand ~~December~~June 3125, 2014., Itrespectfully, iswith ~~anticipated~~the understanding that such short-term advances would have an interest rate similar to a factoring loan, would be secured by certain receivables of Bioject, in the case of Mr. ~~Chow’s~~Ness ~~salary~~would ~~will~~ be ~~adjusted~~guaranteed ~~upward~~by toMark ~~market~~Logomasini ~~rates~~and the SEP would not incur losses. The notes have a simple, ifnon-compounded ~~the~~monthly ~~financial~~interest ~~condition~~rate of ~~the~~2% ~~Company~~and ~~improves~~mature on August 22, 2014.

Mr. Chow will be eligible for stock option grants and other incentive compensation as determined by the Board of Directors of the Company.

This Agreement has an initial term of one (1) year, subject to the early termination provisions set forth in the Agreement. Upon expiration of the initial term, this Agreement will be automatically extended for additional one-year terms unless Mr. Chow or the Company shall, upon 120 days written notice to the other, elect not to extend this Agreement for an additional one-year term.

Under certain conditions, Mr. Chow will receive severance benefits as follows:

• three (3) months of Mr. Chow’s then-current Base Salary plus accrued and unused vacation (the “Severance Pay”); and

• an amount equivalent to the premium Mr. Chow would pay if he were to elect to continue his group health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for a period of three (3) months.

There are no agreements or understandings between Mr. Chow and any other person regarding Mr. Chow’s selection as an executive officer. There are no family relationships between Mr. Chow and any other Director or officer of the Company.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following ~~exhibit~~exhibits isare filed or furnished herewith and this list is intended to constitute the exhibit index:

10.1* Executive Employment Agreement dated July 1, 2014 between Bioject Medical Technologies Inc., Bioject Inc. and Tony K. Chow.



10.1		Form of Note from Bioject to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $100,000, dated June 23, 2014.

10.2		Form of Note from Bioject to Amir Ness in the principal amount of $50,000, dated June 25, 2014.

10.3		Form of Security Agreement by and among Bioject, the SEP and Amir Ness dated June 25, 2014.

99.1		Press release issued by Bioject Medical Technologies Inc. dated August 15, 2014.

* Management or compensatory arrangement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 3, 2014		BIOJECT MEDICAL TECHNOLOGIES INC.
Date: August 15, 2014	BIOJECT MEDICAL TECHNOLOGIES INC. (Registrant)
		(Registrant)
	/s/ Tony K. Chow
		/s/ Mark A. Logomasini
	Tony K. Chow
		Mark A. Logomasini
	Chief Financial Officer
		President and Chief Executive Officer
	(Principal Financial and Accounting Officer)
		(Principal Executive Officer)

Filing Compare · BIOJECT MEDICAL TECHNOLOGIES INC